Apheresis Market by Product (Device, Disposable), Procedure [Donor, Therapeutic (Neurological, Blood)], Application (Plasmapheresis, Plateletpheresis), Technology (Centrifugation, Membrane Separation), End User (Clinic) - Global Forecast to 2031
The global apheresis market is projected to reach USD 4.41 billion by 2031 from USD 3.02 billion in 2026, growing at a CAGR of 7.9% during the forecast period.
The demand for apheresis equipment and techniques is growing steadily, driven by the rising incidence of hematological, autoimmune, neurological, and renal diseases, as well as the high demand for blood components and plasma-based products worldwide. Increasing use of therapeutic and donor apheresis techniques in hospitals, blood banks, and specialized clinics is supporting the growth of the market. Healthcare facilities are now focusing on developing highly efficient, fully automated, and patient-friendly apheresis systems to increase collection efficacy and improve patient outcomes. Additionally, technological innovations, including automated blood component separators and continuous flow centrifuges, are contributing to market growth. Moreover, improved blood collection facilities in developing countries and healthcare organizations' initiatives ensure effective blood management and are expected to sustain strong market growth in the coming years.
“By product, the disposables are projected to capture a significant market share.”
By product, the disposables category holds the largest share of the global apheresis market, driven by rising numbers of blood collections and therapeutic apheresis procedures worldwide. Disposable kits, tubing assemblies, needles, and collection chambers are vital components of apheresis systems, as they ensure sterility, minimize the risk of contamination, and safeguard patients and donors. The repeated consumption of disposables and their replacement at each new apheresis procedure play a significant role in generating consistent revenue and ensuring product demand. The growing number of plasma collection, plateletpheresis, leukapheresis, and therapeutic plasma exchange procedures is another important factor driving growth in the disposables category. In addition, the increasing demand for plasma-based therapeutics, the rise in blood donations, and the growing acceptance of automated apheresis technology are contributing to the growing use of disposables.
“By procedure, the plasmapheresis segment is expected to register the highest share in 2025.”
By procedure, the plasmapheresis segment holds the largest market share in the apheresis market, driven by growing worldwide demand for plasma-derived therapies used to treat immunological, neurological, and hematological conditions. The plasmapheresis method is widely applied for obtaining donor plasma as well as conducting plasma exchange therapy, since it is highly efficient in plasma separation and collection while other components of the blood are returned to the body. Growth in the incidence of autoimmune diseases, higher demand for immunoglobulins and coagulation factors, and an increasing number of plasma donations worldwide are additional factors supporting the segment's growth. Additionally, the widespread use of plasmapheresis procedures in blood centers and hospitals is facilitated by recent developments in automated plasmapheresis technology, which increase process efficiency and improve donor safety and productivity.
In 2025, North America accounted for the largest market share of the apheresis market by region.
The apheresis market is segmented into North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America leads the global apheresis market; this dominance is attributed to the high incidence of hematological, autoimmune, neurological, and renal disorders, as well as robust demand for plasma-based products and blood components. The region benefits from an extensive healthcare and blood donation network, widespread use of apheresis techniques, and the involvement of major market players and plasma collection companies. In addition, increased awareness of blood donation, rising cases of apheresis treatment, favorable reimbursement policies, and investment in transfusion medicine and plasma collection facilities contribute to the market's dominance in the region.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report examines the apheresis market by product, type, procedure, technology, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions).
Reasons to Buy the Report
The report will enable established firms, as well as entrants/smaller firms, to gauge the market pulse, which, in turn, will help them gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.
This report provides insights into the following pointers:
Analysis of key drivers (rising prevalence of autoimmune and neurological disorders, increasing utilization of plasma-derived biologics by biopharmaceutical companies, rising demand for blood components, increasing emphasis on transfusion safety, growing volume of complex oncological and transplant procedures, technological improvements in component-specific blood collection, and expanding adoption of cell and gene therapies), restraints (high procedural and operational costs limiting adoption of apheresis technologies, limited adoption of apheresis donation procedures in emerging economies, stringent donor eligibility criteria and limited donor availability restraining apheresis procedures and dearth of skilled professionals impacting the adoption of apheresis procedures), opportunities (adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities for the apheresis market, and growing investments in emerging markets by governments and key industry players), and challenges (risk of procedure-related adverse events and risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries) influencing the growth of apheresis market
The demand for apheresis equipment and techniques is growing steadily, driven by the rising incidence of hematological, autoimmune, neurological, and renal diseases, as well as the high demand for blood components and plasma-based products worldwide. Increasing use of therapeutic and donor apheresis techniques in hospitals, blood banks, and specialized clinics is supporting the growth of the market. Healthcare facilities are now focusing on developing highly efficient, fully automated, and patient-friendly apheresis systems to increase collection efficacy and improve patient outcomes. Additionally, technological innovations, including automated blood component separators and continuous flow centrifuges, are contributing to market growth. Moreover, improved blood collection facilities in developing countries and healthcare organizations' initiatives ensure effective blood management and are expected to sustain strong market growth in the coming years.
“By product, the disposables are projected to capture a significant market share.”
By product, the disposables category holds the largest share of the global apheresis market, driven by rising numbers of blood collections and therapeutic apheresis procedures worldwide. Disposable kits, tubing assemblies, needles, and collection chambers are vital components of apheresis systems, as they ensure sterility, minimize the risk of contamination, and safeguard patients and donors. The repeated consumption of disposables and their replacement at each new apheresis procedure play a significant role in generating consistent revenue and ensuring product demand. The growing number of plasma collection, plateletpheresis, leukapheresis, and therapeutic plasma exchange procedures is another important factor driving growth in the disposables category. In addition, the increasing demand for plasma-based therapeutics, the rise in blood donations, and the growing acceptance of automated apheresis technology are contributing to the growing use of disposables.
“By procedure, the plasmapheresis segment is expected to register the highest share in 2025.”
By procedure, the plasmapheresis segment holds the largest market share in the apheresis market, driven by growing worldwide demand for plasma-derived therapies used to treat immunological, neurological, and hematological conditions. The plasmapheresis method is widely applied for obtaining donor plasma as well as conducting plasma exchange therapy, since it is highly efficient in plasma separation and collection while other components of the blood are returned to the body. Growth in the incidence of autoimmune diseases, higher demand for immunoglobulins and coagulation factors, and an increasing number of plasma donations worldwide are additional factors supporting the segment's growth. Additionally, the widespread use of plasmapheresis procedures in blood centers and hospitals is facilitated by recent developments in automated plasmapheresis technology, which increase process efficiency and improve donor safety and productivity.
In 2025, North America accounted for the largest market share of the apheresis market by region.
The apheresis market is segmented into North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America leads the global apheresis market; this dominance is attributed to the high incidence of hematological, autoimmune, neurological, and renal disorders, as well as robust demand for plasma-based products and blood components. The region benefits from an extensive healthcare and blood donation network, widespread use of apheresis techniques, and the involvement of major market players and plasma collection companies. In addition, increased awareness of blood donation, rising cases of apheresis treatment, favorable reimbursement policies, and investment in transfusion medicine and plasma collection facilities contribute to the market's dominance in the region.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–40%, Tier 2–35%, and Tier 3– 25%
- By Designation: Directors–23%, Managers–30%, and Others–47%
- By Region: North America–25%, Europe–35%, the Asia Pacific–20%, Latin America- 13%, and the Middle East & Africa- 7%
Research Coverage
This report examines the apheresis market by product, type, procedure, technology, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions).
Reasons to Buy the Report
The report will enable established firms, as well as entrants/smaller firms, to gauge the market pulse, which, in turn, will help them gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.
This report provides insights into the following pointers:
Analysis of key drivers (rising prevalence of autoimmune and neurological disorders, increasing utilization of plasma-derived biologics by biopharmaceutical companies, rising demand for blood components, increasing emphasis on transfusion safety, growing volume of complex oncological and transplant procedures, technological improvements in component-specific blood collection, and expanding adoption of cell and gene therapies), restraints (high procedural and operational costs limiting adoption of apheresis technologies, limited adoption of apheresis donation procedures in emerging economies, stringent donor eligibility criteria and limited donor availability restraining apheresis procedures and dearth of skilled professionals impacting the adoption of apheresis procedures), opportunities (adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities for the apheresis market, and growing investments in emerging markets by governments and key industry players), and challenges (risk of procedure-related adverse events and risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries) influencing the growth of apheresis market
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the apheresis market
- Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product developments in the apheresis market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the apheresis market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 PRODUCT DEFINITION
1.2.2 TECHNOLOGY DEFINITION
1.2.3 PROCEDURE DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN APHERESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 APHERESIS MARKET OVERVIEW
3.2 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY AND END USER
3.3 GEOGRAPHIC SNAPSHOT OF APHERESIS MARKET
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of autoimmune and neurological disorders driving demand for therapeutic apheresis procedures
4.2.1.2 Rising demand for blood components and increasing emphasis on transfusion safety to support market expansion
4.2.1.3 Growing volume of complex oncological and transplant procedures to support growth of apheresis
4.2.1.4 Technological improvements in component-specific blood collection to support market expansion
4.2.1.5 Expanding adoption of cell and gene therapies to create growth opportunities for apheresis market
4.2.2 RESTRAINTS
4.2.2.1 High procedural and operational costs limit adoption of apheresis technologies
4.2.2.2 Limited adoption of apheresis donation procedures in emerging economies
4.2.2.3 Stringent donor eligibility criteria and limited donor availability to restrain apheresis procedures
4.2.2.4 Dearth of skilled professionals impacting adoption of apheresis procedures
4.2.3 OPPORTUNITIES
4.2.3.1 Adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities
4.2.3.2 Growing investments in emerging markets by governments and key industry players
4.2.4 CHALLENGES
4.2.4.1 Risk of procedure-related adverse events and donor safety concerns
4.2.4.2 Risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN APHERESIS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES IN APHERESIS MARKET
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT FROM NEW ENTRANTS
5.1.2 THREAT FROM SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 MANUFACTURERS
5.5.2 END USERS
5.5.3 REGULATORY BODIES
5.6 PRICING ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA (HS CODE 901890)
5.7.2 EXPORT DATA FOR (HS CODE 901890)
5.8 REIMBURSEMENT SCENARIO
5.9 KEY CONFERENCES & EVENTS, 2026–2027
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 CASE STUDY ANALYSIS
5.13 IMPACT OF 2025 US TARIFF
5.13.1 INTRODUCTION
5.13.2 KEY TARIFF RATES
5.13.3 PRICE IMPACT ANALYSIS
5.13.4 IMPACT ON COUNTRY/REGION
5.13.5 IMPACT ON END-USE SEGMENTS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Automation and AI-enabled procedure optimization in apheresis systems
6.1.1.2 Closed-loop and automated cell therapy collection/manufacturing workflows
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Real-time biosensors and digital monitoring in apheresis procedures
6.1.2.2 RFID, barcode, and digital traceability technologies in blood and cell collection management
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Cell and gene therapy manufacturing technologies
6.1.3.2 Therapeutic filtration, adsorption, and extracorporeal blood purification technologies
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.2.1 NEAR TERM (2025–2027)
6.2.2 MID-TERM (2028–2030)
6.2.3 LONG TERM (2030+)
6.3 PATENT ANALYSIS
6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS
6.4 FUTURE APPLICATIONS
6.4.1 AI-ENABLED AND DATA-DRIVEN APHERESIS PROCEDURE OPTIMIZATION
6.4.2 PERSONALIZED THERAPEUTIC APHERESIS
6.4.3 CONNECTED APHERESIS WORKFLOWS AND DIGITAL TRACEABILITY
6.5 IMPACT OF AI/GEN AI ON APHERESIS
6.5.1 INTRODUCTION
6.5.2 MARKET POTENTIAL OF AI IN APHERESIS
6.5.3 AI USE CASES
6.5.4 KEY COMPANIES IMPLEMENTING AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGULATORY LANDSCAPE
7.1.1 REGULATORY FRAMEWORK
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Asia Pacific
7.1.1.4 Latin America
7.1.1.5 Middle East & Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 REDUCING SINGLE-USE APHERESIS WASTE
7.2.2 USE OF LOWER-IMPACT MATERIALS AND PACKAGING
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 APHERESIS MARKET, BY TYPE
9.1 INTRODUCTION
9.2 DONOR APHERESIS
9.2.1 INCREASING BLOOD DONATIONS AND EXPANDING CELL THERAPY COLLECTIONS TO SUPPORT DONOR APHERESIS MARKET GROWTH
9.3 THERAPEUTIC APHERESIS
9.3.1 GROWING CLINICAL UTILIZATION OF THERAPEUTIC PLASMA EXCHANGE AND EXPANDING NEUROLOGICAL APPLICATIONS TO DRIVE MARKET
9.4 NEUROLOGICAL DISORDERS
9.4.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
9.5 BLOOD DISORDERS
9.5.1 RISING PREVALENCE OF HEMATOLOGICAL AND GENETIC BLOOD DISORDERS TO DRIVE DEMAND
9.6 RENAL DISORDERS
9.6.1 RISING BURDEN OF CHRONIC KIDNEY DISEASE AND AUTOIMMUNE RENAL COMPLICATIONS TO DRIVE DEMAND
9.7 AUTOIMMUNE DISORDERS
9.7.1 INCREASING PREVALENCE OF AUTOIMMUNE DISORDERS AND CONTINUED CLINICAL IMPORTANCE OF THERAPEUTIC APHERESIS TO DRIVE GROWTH
9.8 METABOLIC DISORDERS
9.8.1 GROWING BURDEN OF DIABETES AND METABOLIC CONDITIONS TO SUPPORT THERAPEUTIC APHERESIS MARKET GROWTH
9.9 CARDIOVASCULAR DISORDERS
9.9.1 RISING LONG-TERM BURDEN OF CARDIOVASCULAR DISORDERS TO DRIVE MARKET GROWTH
9.10 OTHER DISORDERS
10 APHERESIS MARKET, BY END USER
10.1 INTRODUCTION
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
10.2.1 INCREASING DEMAND FOR COMPONENT-SPECIFIC BLOOD COLLECTION AND COMMERCIAL PLASMA SUPPLY TO DRIVE MARKET GROWTH
10.3 HOSPITALS & TRANSFUSION CENTERS
10.3.1 EXPANDING TRANSFUSION REQUIREMENTS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
10.4 OTHER END USERS
11 APHERESIS MARKET, BY PROCEDURE
11.1 INTRODUCTION
11.2 PLASMAPHERESIS
11.2.1 INCREASING GLOBAL DEMAND FOR PLASMA-DERIVED THERAPIES AND THERAPEUTIC PLASMA EXCHANGE TO DRIVE MARKET GROWTH
11.3 PLATELETAPHERESIS
11.3.1 INCREASING DEMAND FOR PLATELET TRANSFUSIONS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
11.4 ERYTHROCYTAPHERESIS
11.4.1 INCREASING BURDEN OF SICKLE CELL DISEASE AND RISING DEMAND FOR TARGETED RED BLOOD CELL EXCHANGE PROCEDURES TO DRIVE GROWTH
11.5 LEUKAPHERESIS
11.5.1 EXPANDING CELL AND GENE THERAPY PIPELINE AND INCREASING CAR-T CELL MANUFACTURING ACTIVITIES TO DRIVE MARKET GROWTH
11.6 PHOTOPHERESIS
11.6.1 INCREASING TRANSPLANT PROCEDURES AND RISING USE OF IMMUNE-MODULATING THERAPIES TO SUPPORT MARKET GROWTH
11.7 OTHER PROCEDURES
12 APHERESIS MARKET, BY PRODUCT
12.1 INTRODUCTION
12.2 APHERESIS DEVICES
12.2.1 RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE SEGMENT GROWTH
12.3 APHERESIS DISPOSABLES
12.3.1 RECURRING UTILIZATION OF SINGLE-USE CONSUMABLES AND RISING THERAPEUTIC PROCEDURE VOLUMES TO DRIVE GROWTH
13 APHERESIS MARKET, BY TECHNOLOGY
13.1 INTRODUCTION
13.2 CENTRIFUGATION
13.3 CONTINUOUS FLOW CENTRIFUGATION
13.3.1 INCREASING NEED FOR HIGH-THROUGHPUT BLOOD COMPONENT COLLECTION AND EFFICIENT PLASMA PROCESSING TO DRIVE GROWTH
13.4 INTERMITTENT FLOW CENTRIFUGATION
13.4.1 INCREASING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE APHERESIS SYSTEMS IN HEALTHCARE SETTINGS TO SUPPORT MARKET GROWTH
13.5 MEMBRANE SEPARATION
13.5.1 INCREASING UTILIZATION OF MEMBRANE-BASED PLASMA FILTRATION TECHNOLOGIES IN THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
14 APHERESIS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Strong economic capacity and high healthcare spending to support north america apheresis market growth
14.2.3 CANADA
14.2.3.1 Rising demand for blood components and plasma protein products to drive market growth
14.3 ASIA PACIFIC
14.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.3.2 CHINA
14.3.2.1 Expanding healthcare infrastructure and growing demand for advanced blood management procedures to accelerate growth
14.3.3 JAPAN
14.3.3.1 Aging-driven treatment demand and advanced hospital infrastructure to support market growth
14.3.4 INDIA
14.3.4.1 Large patient base and expanding healthcare infrastructure to drive market
14.3.5 AUSTRALIA
14.3.5.1 Strong healthcare infrastructure and growing demand for specialized therapies to support market growth
14.3.6 SOUTH KOREA
14.3.6.1 Advanced healthcare technologies and growing specialty care adoption to support market growth
14.3.7 THAILAND
14.3.7.1 Expanding specialty care infrastructure and rising chronic disease burden to support market growth
14.3.8 SINGAPORE
14.3.8.1 Advanced healthcare infrastructure and regional medical hub status to support market growth
14.3.9 REST OF ASIA PACIFIC
14.4 EUROPE
14.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.4.2 GERMANY
14.4.2.1 High healthcare spending and strong reimbursement support to drive market growth
14.4.3 FRANCE
14.4.3.1 Centralized healthcare system and growing therapeutic apheresis utilization to propel growth
14.4.4 ITALY
14.4.4.1 Rising elderly population and growing demand for therapeutic procedures to drive growth
14.4.5 UK
14.4.5.1 Expanding apheresis infrastructure and specialized care services to support market growth
14.4.6 SPAIN
14.4.6.1 Growing chronic disease burden and expanding specialty treatment centers to support market growth
14.4.7 SWITZERLAND
14.4.7.1 Advanced healthcare funding and specialized treatment capabilities to support growth
14.4.8 NETHERLANDS
14.4.8.1 Advanced healthcare infrastructure and strong academic network to support market
14.4.9 REST OF EUROPE
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Cancer burden, blood donation recovery, and CAR-T access to strengthen market growth
14.5.3 MEXICO
14.5.3.1 Expanding leukemia treatment access and rising blood component demand to support market growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 GCC COUNTRIES
14.6.2.1 Expanding advanced healthcare infrastructure and cell therapy capabilities to support market
14.6.3 KINGDOM OF SAUDI ARABIA (KSA)
14.6.3.1 Expanding cell therapy infrastructure and clinical trial ecosystem to support market growth
14.6.3.2 United Arab Emirates (UAE)
14.6.3.2.1 Growing precision medicine initiatives and advanced oncology capabilities to support market growth
14.6.4 OTHER GCC COUNTRIES
14.6.5 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN APHERESIS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 GLOBAL MARKET SHARE ANALYSIS, 2025
15.4.1 US: MARKET SHARE ANALYSIS, 2025
15.4.2 EUROPE: MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product footprint
15.5.5.4 Type footprint
15.5.5.5 Technology footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS (APHERESIS PRODUCTS MARKET)
16.1.1 TERUMO CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 FRESENIUS SE & CO. KGAA
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches
16.1.2.3.2 Other developments
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 FRESENIUS MEDICAL CARE AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.4 MnM view
16.1.3.4.1 Key strengths/Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 HAEMONETICS CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches
16.1.4.4 MnM view
16.1.4.4.1 Key strengths/Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 B. BRAUN SE
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 MnM view
16.1.5.3.1 Key strengths/Right to win
16.1.5.3.2 Strategic choices
16.1.5.3.3 Weaknesses and competitive threats
16.1.6 BD
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Deals
16.1.6.3.2 Expansions
16.1.7 ASAHI KASEI MEDICAL CO., LTD.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Other developments
16.1.8 OTSUKA HOLDINGS CO., LTD.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.9 MEDICA S.P.A
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.10 SUMITOMO BAKELITE CO., LTD.
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 MnM view
16.1.10.3.1 Right to win
16.1.10.3.2 Strategic choices
16.1.10.3.3 Weaknesses & competitive threats
16.1.11 KANEKA CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Deals
16.1.11.3.2 Expansions
16.1.12 VANTIVE
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Deals
16.1.12.3.2 Other developments
16.1.13 MILTENYI BIOTEC
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Deals
16.1.13.3.2 Expansions
16.1.14 NIKKISO CO., LTD.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Deals
16.1.14.3.2 Other developments
16.1.15 TORAY INDUSTRIES, INC.
16.1.15.1 Business overview
16.1.15.2 Products offered
16.2 OTHER PLAYERS
16.2.1 MACOPHARMA SA
16.2.2 INFOMED SA
16.2.3 THERAKOS LLC.
16.2.4 MEDICAP GMBH
16.2.5 HAIER BIOMEDICAL
16.2.6 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.
16.2.7 JAFRON BIOMEDICAL CO., LTD.
16.2.8 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD
16.2.9 KENTEC MEDICAL
16.2.10 SCINOMED LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 Key industry insights
17.2 MARKET SIZE ESTIMATION METHODOLOGY
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.5.1 GROWTH RATE ASSUMPTIONS
17.6 RISK ASSESSMENT
17.7 LIMITATIONS
17.7.1 METHODOLOGY-RELATED LIMITATIONS
17.7.2 SCOPE-RELATED LIMITATIONS
17.8 RESEARCH LIMITATIONS
17.9 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.3.1 COMPANY INFORMATION
18.3.2 COUNTRY ANALYSIS
18.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
18.3.4 COUNTRY-LEVEL VOLUME ANALYSIS
18.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 PRODUCT DEFINITION
1.2.2 TECHNOLOGY DEFINITION
1.2.3 PROCEDURE DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN APHERESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 APHERESIS MARKET OVERVIEW
3.2 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY AND END USER
3.3 GEOGRAPHIC SNAPSHOT OF APHERESIS MARKET
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of autoimmune and neurological disorders driving demand for therapeutic apheresis procedures
4.2.1.2 Rising demand for blood components and increasing emphasis on transfusion safety to support market expansion
4.2.1.3 Growing volume of complex oncological and transplant procedures to support growth of apheresis
4.2.1.4 Technological improvements in component-specific blood collection to support market expansion
4.2.1.5 Expanding adoption of cell and gene therapies to create growth opportunities for apheresis market
4.2.2 RESTRAINTS
4.2.2.1 High procedural and operational costs limit adoption of apheresis technologies
4.2.2.2 Limited adoption of apheresis donation procedures in emerging economies
4.2.2.3 Stringent donor eligibility criteria and limited donor availability to restrain apheresis procedures
4.2.2.4 Dearth of skilled professionals impacting adoption of apheresis procedures
4.2.3 OPPORTUNITIES
4.2.3.1 Adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities
4.2.3.2 Growing investments in emerging markets by governments and key industry players
4.2.4 CHALLENGES
4.2.4.1 Risk of procedure-related adverse events and donor safety concerns
4.2.4.2 Risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN APHERESIS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES IN APHERESIS MARKET
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT FROM NEW ENTRANTS
5.1.2 THREAT FROM SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 MANUFACTURERS
5.5.2 END USERS
5.5.3 REGULATORY BODIES
5.6 PRICING ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA (HS CODE 901890)
5.7.2 EXPORT DATA FOR (HS CODE 901890)
5.8 REIMBURSEMENT SCENARIO
5.9 KEY CONFERENCES & EVENTS, 2026–2027
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 CASE STUDY ANALYSIS
5.13 IMPACT OF 2025 US TARIFF
5.13.1 INTRODUCTION
5.13.2 KEY TARIFF RATES
5.13.3 PRICE IMPACT ANALYSIS
5.13.4 IMPACT ON COUNTRY/REGION
5.13.5 IMPACT ON END-USE SEGMENTS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Automation and AI-enabled procedure optimization in apheresis systems
6.1.1.2 Closed-loop and automated cell therapy collection/manufacturing workflows
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Real-time biosensors and digital monitoring in apheresis procedures
6.1.2.2 RFID, barcode, and digital traceability technologies in blood and cell collection management
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Cell and gene therapy manufacturing technologies
6.1.3.2 Therapeutic filtration, adsorption, and extracorporeal blood purification technologies
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.2.1 NEAR TERM (2025–2027)
6.2.2 MID-TERM (2028–2030)
6.2.3 LONG TERM (2030+)
6.3 PATENT ANALYSIS
6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS
6.4 FUTURE APPLICATIONS
6.4.1 AI-ENABLED AND DATA-DRIVEN APHERESIS PROCEDURE OPTIMIZATION
6.4.2 PERSONALIZED THERAPEUTIC APHERESIS
6.4.3 CONNECTED APHERESIS WORKFLOWS AND DIGITAL TRACEABILITY
6.5 IMPACT OF AI/GEN AI ON APHERESIS
6.5.1 INTRODUCTION
6.5.2 MARKET POTENTIAL OF AI IN APHERESIS
6.5.3 AI USE CASES
6.5.4 KEY COMPANIES IMPLEMENTING AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGULATORY LANDSCAPE
7.1.1 REGULATORY FRAMEWORK
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Asia Pacific
7.1.1.4 Latin America
7.1.1.5 Middle East & Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 REDUCING SINGLE-USE APHERESIS WASTE
7.2.2 USE OF LOWER-IMPACT MATERIALS AND PACKAGING
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 APHERESIS MARKET, BY TYPE
9.1 INTRODUCTION
9.2 DONOR APHERESIS
9.2.1 INCREASING BLOOD DONATIONS AND EXPANDING CELL THERAPY COLLECTIONS TO SUPPORT DONOR APHERESIS MARKET GROWTH
9.3 THERAPEUTIC APHERESIS
9.3.1 GROWING CLINICAL UTILIZATION OF THERAPEUTIC PLASMA EXCHANGE AND EXPANDING NEUROLOGICAL APPLICATIONS TO DRIVE MARKET
9.4 NEUROLOGICAL DISORDERS
9.4.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
9.5 BLOOD DISORDERS
9.5.1 RISING PREVALENCE OF HEMATOLOGICAL AND GENETIC BLOOD DISORDERS TO DRIVE DEMAND
9.6 RENAL DISORDERS
9.6.1 RISING BURDEN OF CHRONIC KIDNEY DISEASE AND AUTOIMMUNE RENAL COMPLICATIONS TO DRIVE DEMAND
9.7 AUTOIMMUNE DISORDERS
9.7.1 INCREASING PREVALENCE OF AUTOIMMUNE DISORDERS AND CONTINUED CLINICAL IMPORTANCE OF THERAPEUTIC APHERESIS TO DRIVE GROWTH
9.8 METABOLIC DISORDERS
9.8.1 GROWING BURDEN OF DIABETES AND METABOLIC CONDITIONS TO SUPPORT THERAPEUTIC APHERESIS MARKET GROWTH
9.9 CARDIOVASCULAR DISORDERS
9.9.1 RISING LONG-TERM BURDEN OF CARDIOVASCULAR DISORDERS TO DRIVE MARKET GROWTH
9.10 OTHER DISORDERS
10 APHERESIS MARKET, BY END USER
10.1 INTRODUCTION
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
10.2.1 INCREASING DEMAND FOR COMPONENT-SPECIFIC BLOOD COLLECTION AND COMMERCIAL PLASMA SUPPLY TO DRIVE MARKET GROWTH
10.3 HOSPITALS & TRANSFUSION CENTERS
10.3.1 EXPANDING TRANSFUSION REQUIREMENTS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
10.4 OTHER END USERS
11 APHERESIS MARKET, BY PROCEDURE
11.1 INTRODUCTION
11.2 PLASMAPHERESIS
11.2.1 INCREASING GLOBAL DEMAND FOR PLASMA-DERIVED THERAPIES AND THERAPEUTIC PLASMA EXCHANGE TO DRIVE MARKET GROWTH
11.3 PLATELETAPHERESIS
11.3.1 INCREASING DEMAND FOR PLATELET TRANSFUSIONS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
11.4 ERYTHROCYTAPHERESIS
11.4.1 INCREASING BURDEN OF SICKLE CELL DISEASE AND RISING DEMAND FOR TARGETED RED BLOOD CELL EXCHANGE PROCEDURES TO DRIVE GROWTH
11.5 LEUKAPHERESIS
11.5.1 EXPANDING CELL AND GENE THERAPY PIPELINE AND INCREASING CAR-T CELL MANUFACTURING ACTIVITIES TO DRIVE MARKET GROWTH
11.6 PHOTOPHERESIS
11.6.1 INCREASING TRANSPLANT PROCEDURES AND RISING USE OF IMMUNE-MODULATING THERAPIES TO SUPPORT MARKET GROWTH
11.7 OTHER PROCEDURES
12 APHERESIS MARKET, BY PRODUCT
12.1 INTRODUCTION
12.2 APHERESIS DEVICES
12.2.1 RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE SEGMENT GROWTH
12.3 APHERESIS DISPOSABLES
12.3.1 RECURRING UTILIZATION OF SINGLE-USE CONSUMABLES AND RISING THERAPEUTIC PROCEDURE VOLUMES TO DRIVE GROWTH
13 APHERESIS MARKET, BY TECHNOLOGY
13.1 INTRODUCTION
13.2 CENTRIFUGATION
13.3 CONTINUOUS FLOW CENTRIFUGATION
13.3.1 INCREASING NEED FOR HIGH-THROUGHPUT BLOOD COMPONENT COLLECTION AND EFFICIENT PLASMA PROCESSING TO DRIVE GROWTH
13.4 INTERMITTENT FLOW CENTRIFUGATION
13.4.1 INCREASING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE APHERESIS SYSTEMS IN HEALTHCARE SETTINGS TO SUPPORT MARKET GROWTH
13.5 MEMBRANE SEPARATION
13.5.1 INCREASING UTILIZATION OF MEMBRANE-BASED PLASMA FILTRATION TECHNOLOGIES IN THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
14 APHERESIS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Strong economic capacity and high healthcare spending to support north america apheresis market growth
14.2.3 CANADA
14.2.3.1 Rising demand for blood components and plasma protein products to drive market growth
14.3 ASIA PACIFIC
14.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.3.2 CHINA
14.3.2.1 Expanding healthcare infrastructure and growing demand for advanced blood management procedures to accelerate growth
14.3.3 JAPAN
14.3.3.1 Aging-driven treatment demand and advanced hospital infrastructure to support market growth
14.3.4 INDIA
14.3.4.1 Large patient base and expanding healthcare infrastructure to drive market
14.3.5 AUSTRALIA
14.3.5.1 Strong healthcare infrastructure and growing demand for specialized therapies to support market growth
14.3.6 SOUTH KOREA
14.3.6.1 Advanced healthcare technologies and growing specialty care adoption to support market growth
14.3.7 THAILAND
14.3.7.1 Expanding specialty care infrastructure and rising chronic disease burden to support market growth
14.3.8 SINGAPORE
14.3.8.1 Advanced healthcare infrastructure and regional medical hub status to support market growth
14.3.9 REST OF ASIA PACIFIC
14.4 EUROPE
14.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.4.2 GERMANY
14.4.2.1 High healthcare spending and strong reimbursement support to drive market growth
14.4.3 FRANCE
14.4.3.1 Centralized healthcare system and growing therapeutic apheresis utilization to propel growth
14.4.4 ITALY
14.4.4.1 Rising elderly population and growing demand for therapeutic procedures to drive growth
14.4.5 UK
14.4.5.1 Expanding apheresis infrastructure and specialized care services to support market growth
14.4.6 SPAIN
14.4.6.1 Growing chronic disease burden and expanding specialty treatment centers to support market growth
14.4.7 SWITZERLAND
14.4.7.1 Advanced healthcare funding and specialized treatment capabilities to support growth
14.4.8 NETHERLANDS
14.4.8.1 Advanced healthcare infrastructure and strong academic network to support market
14.4.9 REST OF EUROPE
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Cancer burden, blood donation recovery, and CAR-T access to strengthen market growth
14.5.3 MEXICO
14.5.3.1 Expanding leukemia treatment access and rising blood component demand to support market growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 GCC COUNTRIES
14.6.2.1 Expanding advanced healthcare infrastructure and cell therapy capabilities to support market
14.6.3 KINGDOM OF SAUDI ARABIA (KSA)
14.6.3.1 Expanding cell therapy infrastructure and clinical trial ecosystem to support market growth
14.6.3.2 United Arab Emirates (UAE)
14.6.3.2.1 Growing precision medicine initiatives and advanced oncology capabilities to support market growth
14.6.4 OTHER GCC COUNTRIES
14.6.5 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN APHERESIS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 GLOBAL MARKET SHARE ANALYSIS, 2025
15.4.1 US: MARKET SHARE ANALYSIS, 2025
15.4.2 EUROPE: MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product footprint
15.5.5.4 Type footprint
15.5.5.5 Technology footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS (APHERESIS PRODUCTS MARKET)
16.1.1 TERUMO CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 FRESENIUS SE & CO. KGAA
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches
16.1.2.3.2 Other developments
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 FRESENIUS MEDICAL CARE AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.4 MnM view
16.1.3.4.1 Key strengths/Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 HAEMONETICS CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches
16.1.4.4 MnM view
16.1.4.4.1 Key strengths/Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 B. BRAUN SE
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 MnM view
16.1.5.3.1 Key strengths/Right to win
16.1.5.3.2 Strategic choices
16.1.5.3.3 Weaknesses and competitive threats
16.1.6 BD
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Deals
16.1.6.3.2 Expansions
16.1.7 ASAHI KASEI MEDICAL CO., LTD.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Other developments
16.1.8 OTSUKA HOLDINGS CO., LTD.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.9 MEDICA S.P.A
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.10 SUMITOMO BAKELITE CO., LTD.
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 MnM view
16.1.10.3.1 Right to win
16.1.10.3.2 Strategic choices
16.1.10.3.3 Weaknesses & competitive threats
16.1.11 KANEKA CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Deals
16.1.11.3.2 Expansions
16.1.12 VANTIVE
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Deals
16.1.12.3.2 Other developments
16.1.13 MILTENYI BIOTEC
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Deals
16.1.13.3.2 Expansions
16.1.14 NIKKISO CO., LTD.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Deals
16.1.14.3.2 Other developments
16.1.15 TORAY INDUSTRIES, INC.
16.1.15.1 Business overview
16.1.15.2 Products offered
16.2 OTHER PLAYERS
16.2.1 MACOPHARMA SA
16.2.2 INFOMED SA
16.2.3 THERAKOS LLC.
16.2.4 MEDICAP GMBH
16.2.5 HAIER BIOMEDICAL
16.2.6 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.
16.2.7 JAFRON BIOMEDICAL CO., LTD.
16.2.8 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD
16.2.9 KENTEC MEDICAL
16.2.10 SCINOMED LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 Key industry insights
17.2 MARKET SIZE ESTIMATION METHODOLOGY
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.5.1 GROWTH RATE ASSUMPTIONS
17.6 RISK ASSESSMENT
17.7 LIMITATIONS
17.7.1 METHODOLOGY-RELATED LIMITATIONS
17.7.2 SCOPE-RELATED LIMITATIONS
17.8 RESEARCH LIMITATIONS
17.9 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.3.1 COMPANY INFORMATION
18.3.2 COUNTRY ANALYSIS
18.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
18.3.4 COUNTRY-LEVEL VOLUME ANALYSIS
18.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 CURRENCY CONVERSION RATES, 2023–2026
TABLE 2 INDICATIVE BLOOD AND BLOOD COMPONENT UTILIZATION ACROSS MAJOR SURGICAL AND CLINICAL CONDITIONS
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION, 2024–2025
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
TABLE 5 RECENT INVESTMENTS AND STRATEGIC ACTIVITIES IN CELL & GENE THERAPY ECOSYSTEM
TABLE 6 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 8 LIST OF KEY APHERESIS MANUFACTURERS
TABLE 9 LIST OF KEY END USERS
TABLE 10 LIST OF KEY REGULATORY BODIES
TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
TABLE 12 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 14 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 15 KEY US BILLING CODES USED FOR APHERESIS PROCEDURES
TABLE 16 US AVERAGE MEDICARE OUTPATIENT PAYMENT
TABLE 17 APHERESIS MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027
TABLE 18 FRESENIUS SE & CO. KGAA AMICUS APHERESIS DEVICE — THERAPEUTIC APHERESIS IN MYASTHENIA GRAVIS PATIENT
TABLE 19 TERUMO BCT’S SPECTRA OPTIA APHERESIS DEVICE — SWITCH FROM MANUAL TO AUTOMATED RED BLOOD CELL EXCHANGE IN BRAZIL
TABLE 20 TERUMO BCT + BOSTON CHILDREN’S HOSPITAL — OPTIMIZING STEM CELL COLLECTION IN SICKLE CELL DISEASE
TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024
TABLE 22 KEY PRODUCT-RELATED TARIFF
TABLE 23 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA
TABLE 24 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA
TABLE 25 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK
TABLE 26 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO
TABLE 27 APHERESIS MARKET: KEY PATENTS, 2023–2025
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF APHERESIS
TABLE 34 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
TABLE 35 APHERESIS MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 36 APHERESIS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
TABLE 37 APHERESIS MARKET: KEY PROFITABILITY DRIVERS
TABLE 38 APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 39 DONOR APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 THERAPEUTIC APHERESIS MARKET, BY DISEASE TYPE, 2024–2031 (USD MILLION)
TABLE 42 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 43 BLOOD DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 RENAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 METABOLIC DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 OTHER DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 50 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 HOSPITALS & TRANSFUSION CENTERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 OTHER END USERS: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 54 PLASMAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 55 PLATELETAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 ERYTHROCYTAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 57 LEUKAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 PHOTOPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 OTHER PROCEDURES: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 61 APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 62 COMMERCIAL APHERESIS DEVICES
TABLE 63 APHERESIS DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 COMMERCIAL APHERESIS DISPOSABLES
TABLE 65 APHERESIS DISPOSABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 COMMERCIAL CENTRIFUGATION TECHNOLOGY DEVICES
TABLE 68 CENTRIFUGATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 69 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 70 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 71 SIZE OF BLOOD COMPONENTS
TABLE 72 COMMERCIAL MEMBRANE SEPARATION DEVICES
TABLE 73 MEMBRANE SEPARATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 APHERESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 MAJOR APHERESIS MARKET PLAYERS IN NORTH AMERICA
TABLE 76 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 83 US: KEY MACROINDICATORS
TABLE 84 US: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 85 US: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 US: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 87 US: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 88 US: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 89 CANADA: KEY MACROINDICATORS
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 91 CANADA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 93 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 95 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 102 CHINA: KEY MACROINDICATORS
TABLE 103 CHINA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 104 CHINA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 CHINA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 106 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 107 CHINA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 108 JAPAN: KEY MACROINDICATORS
TABLE 109 JAPAN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 110 JAPAN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 112 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 113 JAPAN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 INDIA: KEY MACROINDICATORS
TABLE 115 INDIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 116 INDIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 INDIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 118 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 119 INDIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 120 AUSTRALIA: KEY MACROINDICATORS
TABLE 121 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 122 AUSTRALIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 124 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 125 AUSTRALIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 126 SOUTH KOREA: KEY MACROINDICATORS
TABLE 127 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 128 SOUTH KOREA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 130 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 131 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 132 THAILAND: KEY MACROINDICATORS
TABLE 133 THAILAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 134 THAILAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 THAILAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 136 THAILAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 137 THAILAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 138 SINGAPORE: KEY MACROINDICATORS
TABLE 139 SINGAPORE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 140 SINGAPORE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 SINGAPORE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 142 SINGAPORE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 143 SINGAPORE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 145 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 147 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 148 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 156 GERMANY: KEY MACROINDICATORS
TABLE 157 GERMANY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 158 GERMANY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 160 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 161 GERMANY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 162 FRANCE: KEY MACROINDICATORS
TABLE 163 FRANCE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 164 FRANCE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 166 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 167 FRANCE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 168 ITALY: KEY MACROINDICATORS
TABLE 169 ITALY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 170 ITALY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 ITALY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 172 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 173 ITALY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 174 UK: KEY MACROINDICATORS
TABLE 175 UK: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 176 UK: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 UK: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 178 UK: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 179 UK: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 180 SPAIN: KEY MACROINDICATORS
TABLE 181 SPAIN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 182 SPAIN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 184 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 185 SPAIN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 186 SWITZERLAND: KEY MACROINDICATORS
TABLE 187 SWITZERLAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 188 SWITZERLAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 SWITZERLAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 190 SWITZERLAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 191 SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 192 NETHERLANDS: KEY MACROINDICATORS
TABLE 193 NETHERLANDS: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 194 NETHERLANDS: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 NETHERLANDS: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 196 NETHERLANDS: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 197 NETHERLANDS: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 198 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 199 REST OF EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 200 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 201 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 202 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 205 LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 208 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 210 BRAZIL: KEY MACROINDICATORS
TABLE 211 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 212 BRAZIL: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 214 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 215 BRAZIL: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 216 MEXICO: KEY MACROINDICATORS
TABLE 217 MEXICO: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 218 MEXICO: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 220 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 221 MEXICO: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 222 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 223 REST OF LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 225 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 234 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 237 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 238 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 239 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 240 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 241 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 243 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 244 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 245 UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 246 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 247 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 249 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 250 UNITED ARAB EMIRATES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 251 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 252 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 254 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 255 OTHER GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 256 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 257 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 259 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 260 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY APHERESIS COMPANIES, JANUARY 2023–MAY 2026
TABLE 262 APHERESIS MARKET: DEGREE OF COMPETITION
TABLE 263 APHERESIS MARKET: REGION FOOTPRINT
TABLE 264 APHERESIS MARKET: PRODUCT FOOTPRINT
TABLE 265 APHERESIS MARKET: TYPE FOOTPRINT
TABLE 266 APHERESIS MARKET: TECHNOLOGY FOOTPRINT
TABLE 267 APHERESIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 268 APHERESIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 269 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 270 APHERESIS MARKET: DEALS, JANUARY 2023–MAY 2026
TABLE 271 APHERESIS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 272 TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 273 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 274 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 275 TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 276 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 277 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
TABLE 278 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
TABLE 279 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 280 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MAY 2026
TABLE 281 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 282 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW
TABLE 283 FRESENIUS MEDICAL CARE CORPORATION: PRODUCTS OFFERED
TABLE 284 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2023–MAY 2026
TABLE 285 HAEMONETICS CORPORATION: COMPANY OVERVIEW
TABLE 286 HAEMONETICS CORPORATION: PRODUCTS OFFERED
TABLE 287 HAEMONETICS CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 288 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 289 B. BRAUN SE: COMPANY OVERVIEW
TABLE 290 BD: COMPANY OVERVIEW
TABLE 291 BD: PRODUCTS OFFERED
TABLE 292 BD: DEALS, JANUARY 2023–MAY 2026
TABLE 293 BD: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 294 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW
TABLE 295 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED
TABLE 296 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 297 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW
TABLE 298 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED
TABLE 299 MEDICA S.P.A: COMPANY OVERVIEW
TABLE 300 MEDICA S.P.A: PRODUCTS OFFERED
TABLE 301 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW
TABLE 302 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED
TABLE 303 KANEKA CORPORATION: COMPANY OVERVIEW
TABLE 304 KANEKA CORPORATION: PRODUCTS OFFERED
TABLE 305 KANEKA CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 306 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 307 VANTIVE: COMPANY OVERVIEW
TABLE 308 VANTIVE: PRODUCTS OFFERED
TABLE 309 VANTIVE: DEALS, JANUARY 2023–MAY 2026
TABLE 310 VANTIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 311 MILTENYI BIOTEC: COMPANY OVERVIEW
TABLE 312 MILTENYI BIOTEC: PRODUCTS OFFERED
TABLE 313 MILTENYI BIOTEC: DEALS, JANUARY 2023–MAY 2026
TABLE 314 MILTENYI BIOTEC: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 315 NIKKISO CO., LTD.: COMPANY OVERVIEW
TABLE 316 NIKKISO CO., LTD.: PRODUCTS OFFERED
TABLE 317 NIKKISO CO., LTD: DEALS, JANUARY 2023–MAY 2026
TABLE 318 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 319 TORAY INDUSTRIES, INC.: COMPANY OVERVIEW
TABLE 320 TORAY INDUSTRIES, INC.: PRODUCTS OFFERED
TABLE 321 MACOPHARMA SA: COMPANY OVERVIEW
TABLE 322 INFOMED SA: COMPANY OVERVIEW
TABLE 323 THERAKOS LLC.: COMPANY OVERVIEW
TABLE 324 MEDICAP GMBH: COMPANY OVERVIEW
TABLE 325 HAIER BIOMEDICAL: COMPANY OVERVIEW
TABLE 326 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.: COMPANY OVERVIEW
TABLE 327 JAFRON BIOMEDICAL CO., LTD.: COMPANY OVERVIEW
TABLE 328 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD: COMPANY OVERVIEW
TABLE 329 KENTEC MEDICAL: COMPANY OVERVIEW
TABLE 330 SCINOMED LTD.: COMPANY OVERVIEW
TABLE 331 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON APHERESIS MARKET
TABLE 1 CURRENCY CONVERSION RATES, 2023–2026
TABLE 2 INDICATIVE BLOOD AND BLOOD COMPONENT UTILIZATION ACROSS MAJOR SURGICAL AND CLINICAL CONDITIONS
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION, 2024–2025
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
TABLE 5 RECENT INVESTMENTS AND STRATEGIC ACTIVITIES IN CELL & GENE THERAPY ECOSYSTEM
TABLE 6 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 8 LIST OF KEY APHERESIS MANUFACTURERS
TABLE 9 LIST OF KEY END USERS
TABLE 10 LIST OF KEY REGULATORY BODIES
TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
TABLE 12 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 14 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 15 KEY US BILLING CODES USED FOR APHERESIS PROCEDURES
TABLE 16 US AVERAGE MEDICARE OUTPATIENT PAYMENT
TABLE 17 APHERESIS MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027
TABLE 18 FRESENIUS SE & CO. KGAA AMICUS APHERESIS DEVICE — THERAPEUTIC APHERESIS IN MYASTHENIA GRAVIS PATIENT
TABLE 19 TERUMO BCT’S SPECTRA OPTIA APHERESIS DEVICE — SWITCH FROM MANUAL TO AUTOMATED RED BLOOD CELL EXCHANGE IN BRAZIL
TABLE 20 TERUMO BCT + BOSTON CHILDREN’S HOSPITAL — OPTIMIZING STEM CELL COLLECTION IN SICKLE CELL DISEASE
TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024
TABLE 22 KEY PRODUCT-RELATED TARIFF
TABLE 23 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA
TABLE 24 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA
TABLE 25 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK
TABLE 26 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO
TABLE 27 APHERESIS MARKET: KEY PATENTS, 2023–2025
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF APHERESIS
TABLE 34 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
TABLE 35 APHERESIS MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 36 APHERESIS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
TABLE 37 APHERESIS MARKET: KEY PROFITABILITY DRIVERS
TABLE 38 APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 39 DONOR APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 THERAPEUTIC APHERESIS MARKET, BY DISEASE TYPE, 2024–2031 (USD MILLION)
TABLE 42 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 43 BLOOD DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 RENAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 METABOLIC DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 OTHER DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 50 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 HOSPITALS & TRANSFUSION CENTERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 OTHER END USERS: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 54 PLASMAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 55 PLATELETAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 ERYTHROCYTAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 57 LEUKAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 PHOTOPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 OTHER PROCEDURES: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 61 APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 62 COMMERCIAL APHERESIS DEVICES
TABLE 63 APHERESIS DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 COMMERCIAL APHERESIS DISPOSABLES
TABLE 65 APHERESIS DISPOSABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 COMMERCIAL CENTRIFUGATION TECHNOLOGY DEVICES
TABLE 68 CENTRIFUGATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 69 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 70 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 71 SIZE OF BLOOD COMPONENTS
TABLE 72 COMMERCIAL MEMBRANE SEPARATION DEVICES
TABLE 73 MEMBRANE SEPARATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 APHERESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 MAJOR APHERESIS MARKET PLAYERS IN NORTH AMERICA
TABLE 76 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 83 US: KEY MACROINDICATORS
TABLE 84 US: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 85 US: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 US: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 87 US: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 88 US: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 89 CANADA: KEY MACROINDICATORS
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 91 CANADA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 93 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 95 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 102 CHINA: KEY MACROINDICATORS
TABLE 103 CHINA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 104 CHINA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 CHINA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 106 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 107 CHINA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 108 JAPAN: KEY MACROINDICATORS
TABLE 109 JAPAN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 110 JAPAN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 112 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 113 JAPAN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 INDIA: KEY MACROINDICATORS
TABLE 115 INDIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 116 INDIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 INDIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 118 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 119 INDIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 120 AUSTRALIA: KEY MACROINDICATORS
TABLE 121 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 122 AUSTRALIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 124 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 125 AUSTRALIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 126 SOUTH KOREA: KEY MACROINDICATORS
TABLE 127 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 128 SOUTH KOREA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 130 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 131 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 132 THAILAND: KEY MACROINDICATORS
TABLE 133 THAILAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 134 THAILAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 THAILAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 136 THAILAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 137 THAILAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 138 SINGAPORE: KEY MACROINDICATORS
TABLE 139 SINGAPORE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 140 SINGAPORE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 SINGAPORE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 142 SINGAPORE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 143 SINGAPORE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 145 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 147 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 148 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 156 GERMANY: KEY MACROINDICATORS
TABLE 157 GERMANY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 158 GERMANY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 160 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 161 GERMANY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 162 FRANCE: KEY MACROINDICATORS
TABLE 163 FRANCE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 164 FRANCE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 166 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 167 FRANCE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 168 ITALY: KEY MACROINDICATORS
TABLE 169 ITALY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 170 ITALY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 ITALY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 172 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 173 ITALY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 174 UK: KEY MACROINDICATORS
TABLE 175 UK: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 176 UK: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 UK: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 178 UK: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 179 UK: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 180 SPAIN: KEY MACROINDICATORS
TABLE 181 SPAIN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 182 SPAIN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 184 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 185 SPAIN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 186 SWITZERLAND: KEY MACROINDICATORS
TABLE 187 SWITZERLAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 188 SWITZERLAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 SWITZERLAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 190 SWITZERLAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 191 SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 192 NETHERLANDS: KEY MACROINDICATORS
TABLE 193 NETHERLANDS: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 194 NETHERLANDS: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 NETHERLANDS: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 196 NETHERLANDS: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 197 NETHERLANDS: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 198 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 199 REST OF EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 200 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 201 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 202 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 205 LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 208 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 210 BRAZIL: KEY MACROINDICATORS
TABLE 211 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 212 BRAZIL: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 214 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 215 BRAZIL: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 216 MEXICO: KEY MACROINDICATORS
TABLE 217 MEXICO: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 218 MEXICO: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 220 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 221 MEXICO: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 222 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 223 REST OF LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 225 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
TABLE 234 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 237 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 238 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 239 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 240 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 241 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 243 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 244 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 245 UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 246 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 247 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 249 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 250 UNITED ARAB EMIRATES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 251 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 252 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 254 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 255 OTHER GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 256 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 257 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
TABLE 259 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 260 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY APHERESIS COMPANIES, JANUARY 2023–MAY 2026
TABLE 262 APHERESIS MARKET: DEGREE OF COMPETITION
TABLE 263 APHERESIS MARKET: REGION FOOTPRINT
TABLE 264 APHERESIS MARKET: PRODUCT FOOTPRINT
TABLE 265 APHERESIS MARKET: TYPE FOOTPRINT
TABLE 266 APHERESIS MARKET: TECHNOLOGY FOOTPRINT
TABLE 267 APHERESIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 268 APHERESIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 269 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 270 APHERESIS MARKET: DEALS, JANUARY 2023–MAY 2026
TABLE 271 APHERESIS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 272 TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 273 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 274 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 275 TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 276 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 277 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
TABLE 278 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
TABLE 279 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 280 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MAY 2026
TABLE 281 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 282 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW
TABLE 283 FRESENIUS MEDICAL CARE CORPORATION: PRODUCTS OFFERED
TABLE 284 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2023–MAY 2026
TABLE 285 HAEMONETICS CORPORATION: COMPANY OVERVIEW
TABLE 286 HAEMONETICS CORPORATION: PRODUCTS OFFERED
TABLE 287 HAEMONETICS CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 288 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 289 B. BRAUN SE: COMPANY OVERVIEW
TABLE 290 BD: COMPANY OVERVIEW
TABLE 291 BD: PRODUCTS OFFERED
TABLE 292 BD: DEALS, JANUARY 2023–MAY 2026
TABLE 293 BD: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 294 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW
TABLE 295 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED
TABLE 296 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 297 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW
TABLE 298 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED
TABLE 299 MEDICA S.P.A: COMPANY OVERVIEW
TABLE 300 MEDICA S.P.A: PRODUCTS OFFERED
TABLE 301 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW
TABLE 302 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED
TABLE 303 KANEKA CORPORATION: COMPANY OVERVIEW
TABLE 304 KANEKA CORPORATION: PRODUCTS OFFERED
TABLE 305 KANEKA CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 306 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 307 VANTIVE: COMPANY OVERVIEW
TABLE 308 VANTIVE: PRODUCTS OFFERED
TABLE 309 VANTIVE: DEALS, JANUARY 2023–MAY 2026
TABLE 310 VANTIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 311 MILTENYI BIOTEC: COMPANY OVERVIEW
TABLE 312 MILTENYI BIOTEC: PRODUCTS OFFERED
TABLE 313 MILTENYI BIOTEC: DEALS, JANUARY 2023–MAY 2026
TABLE 314 MILTENYI BIOTEC: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 315 NIKKISO CO., LTD.: COMPANY OVERVIEW
TABLE 316 NIKKISO CO., LTD.: PRODUCTS OFFERED
TABLE 317 NIKKISO CO., LTD: DEALS, JANUARY 2023–MAY 2026
TABLE 318 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 319 TORAY INDUSTRIES, INC.: COMPANY OVERVIEW
TABLE 320 TORAY INDUSTRIES, INC.: PRODUCTS OFFERED
TABLE 321 MACOPHARMA SA: COMPANY OVERVIEW
TABLE 322 INFOMED SA: COMPANY OVERVIEW
TABLE 323 THERAKOS LLC.: COMPANY OVERVIEW
TABLE 324 MEDICAP GMBH: COMPANY OVERVIEW
TABLE 325 HAIER BIOMEDICAL: COMPANY OVERVIEW
TABLE 326 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.: COMPANY OVERVIEW
TABLE 327 JAFRON BIOMEDICAL CO., LTD.: COMPANY OVERVIEW
TABLE 328 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD: COMPANY OVERVIEW
TABLE 329 KENTEC MEDICAL: COMPANY OVERVIEW
TABLE 330 SCINOMED LTD.: COMPANY OVERVIEW
TABLE 331 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON APHERESIS MARKET
LIST OF FIGURES
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL APHERESIS MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN APHERESIS MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF APHERESIS MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7 GROWING INCIDENCE OF CHRONIC DISEASES AND WIDER ADOPTION OF THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
FIGURE 8 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2025
FIGURE 9 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 10 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 13 APHERESIS MARKET: VALUE CHAIN ANALYSIS
FIGURE 14 APHERESIS MARKET ECOSYSTEM
FIGURE 15 REVENUE SHIFT AND NEW REVENUE POCKETS FOR APHERESIS MARKET
FIGURE 16 INVESTMENT & FUNDING SCENARIO
FIGURE 17 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS, JANUARY 2015–MAY 2026
FIGURE 18 APHERESIS MARKET: AI USE CASES
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF APHERESIS PRODUCTS
FIGURE 20 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
FIGURE 21 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES, 2025
FIGURE 22 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION)
FIGURE 25 GLOBAL MARKET SHARE ANALYSIS, 2025
FIGURE 26 US: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 27 EUROPE: MARKET SHARE ANALYSIS, 2025
FIGURE 28 APHERESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 APHERESIS MARKET: COMPANY FOOTPRINT
FIGURE 30 APHERESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 EV/EBITDA OF KEY VENDORS
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 APHERESIS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 34 TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 35 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025)
FIGURE 36 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2025)
FIGURE 37 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 38 B. BRAUN SE: COMPANY SNAPSHOT (2025)
FIGURE 39 BD: COMPANY SNAPSHOT (2025)
FIGURE 40 OTSUKA HOLDINGS CO., LTD: COMPANY SNAPSHOT (2025)
FIGURE 41 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 42 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 44 TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 RESEARCH DESIGN
FIGURE 46 PRIMARY SOURCES
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE)
FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 50 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH)
FIGURE 51 APHERESIS MARKET SIZE ANALYSIS, 2025
FIGURE 52 MARKET SIZE ESTIMATION FOR APHERESIS: REVENUE SHARE ANALYSIS
FIGURE 53 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 54 APHERESIS MARKET: CAGR PROJECTIONS, 2026–2031
FIGURE 55 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL APHERESIS MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN APHERESIS MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF APHERESIS MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7 GROWING INCIDENCE OF CHRONIC DISEASES AND WIDER ADOPTION OF THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
FIGURE 8 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2025
FIGURE 9 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 10 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 13 APHERESIS MARKET: VALUE CHAIN ANALYSIS
FIGURE 14 APHERESIS MARKET ECOSYSTEM
FIGURE 15 REVENUE SHIFT AND NEW REVENUE POCKETS FOR APHERESIS MARKET
FIGURE 16 INVESTMENT & FUNDING SCENARIO
FIGURE 17 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS, JANUARY 2015–MAY 2026
FIGURE 18 APHERESIS MARKET: AI USE CASES
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF APHERESIS PRODUCTS
FIGURE 20 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
FIGURE 21 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES, 2025
FIGURE 22 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION)
FIGURE 25 GLOBAL MARKET SHARE ANALYSIS, 2025
FIGURE 26 US: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 27 EUROPE: MARKET SHARE ANALYSIS, 2025
FIGURE 28 APHERESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 APHERESIS MARKET: COMPANY FOOTPRINT
FIGURE 30 APHERESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 EV/EBITDA OF KEY VENDORS
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 APHERESIS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 34 TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 35 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025)
FIGURE 36 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2025)
FIGURE 37 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 38 B. BRAUN SE: COMPANY SNAPSHOT (2025)
FIGURE 39 BD: COMPANY SNAPSHOT (2025)
FIGURE 40 OTSUKA HOLDINGS CO., LTD: COMPANY SNAPSHOT (2025)
FIGURE 41 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 42 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 44 TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 RESEARCH DESIGN
FIGURE 46 PRIMARY SOURCES
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE)
FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 50 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH)
FIGURE 51 APHERESIS MARKET SIZE ANALYSIS, 2025
FIGURE 52 MARKET SIZE ESTIMATION FOR APHERESIS: REVENUE SHARE ANALYSIS
FIGURE 53 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 54 APHERESIS MARKET: CAGR PROJECTIONS, 2026–2031
FIGURE 55 DATA TRIANGULATION METHODOLOGY
